Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
125 hedge funds and large institutions have $957M invested in Verona Pharma in 2024 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 44 increasing their positions, 33 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
33% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 33
11% more funds holding
Funds holding: 113 → 125 (+12)
3% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $10.5M
0.68% more ownership
Funds ownership: 10.34% → 11.02% (+0.68%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
12% less capital invested
Capital invested by funds: $1.08B → $957M (-$128M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$19.2M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$13.9M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11.9M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$11.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$34.1M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$24.2M |
| 3 |
PA
Perceptive Advisors
New York
|
-$19.4M |
| 4 |
FTM
First Turn Management
Del Mar,
California
|
-$15.7M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$14.8M |
VRNA Hedge Fund Activity: Q2 2024 in Review
125 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2024, worth a combined $957M — down 12% from $1.08B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new VRNA positions and 13 closed out — a net gain of 13 holders — while 44 added to existing stakes and 33 trimmed.
The largest buyer was Maverick Capital, adding an estimated $19.2M. The largest seller was Wellington Management Group, cutting an estimated $34.1M.
- 125 institutional investors held Verona Pharma (VRNA) as of Q2 2024, up from 113 in Q1 2024.
- Funds reported $957M of Verona Pharma stock for Q2 2024, down 12% quarter-over-quarter.
- 26 funds opened new Verona Pharma positions in Q2 2024 and 13 closed out, a net change of +13 holders.
- The largest Verona Pharma buyer in Q2 2024 was Maverick Capital, an estimated $19.2M added.
- The largest Verona Pharma seller in Q2 2024 was Wellington Management Group, an estimated $34.1M sold.
Based on aggregated 13F filings for Q2 2024.